Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Deterding

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|June 3, 2022
T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtidePatrick Behrendt, Stephan Traidl, Klaus Hans Wolfgang Böker, et al.
European Journal of Gastroenterology & Hepatology|September 18, 2007
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patientAndrej Potthoff, Katja Deterding, Christian Trautwein, et al.
Medicine|July 14, 2021
Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patientsLaura Scheller, Gudrun Hilgard, Olympia Anastasiou, et al.
Journal of Viral Hepatitis|January 17, 2023
Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patientsLisa Sandmann, Katja Deterding, Birgit Bremer, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohortAntoaneta A Markova, Katja Deterding, Kerstin Port, et al.
Journal of Hepatology|November 28, 2017
Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?Katharina L Hupa, Katja Deterding, Kerstin Port, et al.
The Journal of Infectious Diseases|September 30, 2016
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis CJulia Hengst, Christine Susanne Falk, Verena Schlaphoff, et al.
Zeitschrift Fur Gastroenterologie|December 11, 2023
Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)Lisa Sandmann, Thomas Berg, Katja Deterding, et al.
Zeitschrift Fur Gastroenterologie|December 11, 2023
Lisa Sandmann, Thomas Berg, Katja Deterding, et al.
Journal of Viral Hepatitis|March 16, 2023
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNAKatja Deterding, Chengjian Xu, Kerstin Port, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Liver International : Official Journal of the International Association for the Study of the Liver|June 3, 2022
T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtidePatrick Behrendt, Stephan Traidl, Klaus Hans Wolfgang Böker, et al.
European Journal of Gastroenterology & Hepatology|September 18, 2007
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patientAndrej Potthoff, Katja Deterding, Christian Trautwein, et al.
Medicine|July 14, 2021
Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patientsLaura Scheller, Gudrun Hilgard, Olympia Anastasiou, et al.
Journal of Viral Hepatitis|January 17, 2023
Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patientsLisa Sandmann, Katja Deterding, Birgit Bremer, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohortAntoaneta A Markova, Katja Deterding, Kerstin Port, et al.
Journal of Hepatology|November 28, 2017
Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?Katharina L Hupa, Katja Deterding, Kerstin Port, et al.
The Journal of Infectious Diseases|September 30, 2016
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis CJulia Hengst, Christine Susanne Falk, Verena Schlaphoff, et al.
Zeitschrift Fur Gastroenterologie|December 11, 2023
Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)Lisa Sandmann, Thomas Berg, Katja Deterding, et al.
Zeitschrift Fur Gastroenterologie|December 11, 2023
Lisa Sandmann, Thomas Berg, Katja Deterding, et al.
Journal of Viral Hepatitis|March 16, 2023
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNAKatja Deterding, Chengjian Xu, Kerstin Port, et al.
Pageof 10